Cargando…

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis

BACKGROUND: Transarterial radioembolization (TARE) is increasingly used as an alternative to transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). We aimed to perform an overall and individual patient data (IPD) meta‐analysis of studies comparing TACE and TARE....

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Andrew M., Kassab, Ihab, Massani, Marco, Townsend, Whitney, Singal, Amit G., Soydal, Cigdem, Moreno‐Luna, Laura, Roberts, Lewis R., Chen, Vincent L., Parikh, Neehar D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939158/ https://www.ncbi.nlm.nih.gov/pubmed/35943116 http://dx.doi.org/10.1002/cam4.5125

Ejemplares similares

Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma
por: Singal, Amit G, et al.
Publicado: (2016)

The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma
por: Parikh, Neehar D., et al.
Publicado: (2016)

Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization
por: Kassab, Ihab, et al.
Publicado: (2023)

Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic
por: Mehta, Neil, et al.
Publicado: (2021)

A Biomarker Panel Based upon AFP, Fucosylated Kininogen and PEG-Precipitated IgG Is Highly Accurate for the Early Detection Hepatocellular Carcinoma in Patients with Cirrhosis in Phase II and Phase III Biomarker Evaluation
por: Wang, Mengjun, et al.
Publicado: (2022)

Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis
por: Marquardt, Patrick, et al.
Publicado: (2021)

Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
por: Parikh, Neehar D., et al.
Publicado: (2018)

Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres
por: Bouvry, C., et al.
Publicado: (2018)

The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization
por: Tong, Qianqian, et al.
Publicado: (2022)

Tare Soil Disinfestation from Cyst Nematodes Using Inundation
por: Berger, Beatrice, et al.
Publicado: (2022)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation
por: Lin, Yu, et al.
Publicado: (2022)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Sélection zygotique et tares récessives autosomiques dans une population finie
por: Géry, Gérard
Publicado: (1979)

TACE performed in patients with a single nodule of Hepatocellular Carcinoma
por: Terzi, Eleonora, et al.
Publicado: (2014)

Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma
por: Kong, Lingxiang, et al.
Publicado: (2021)

Predictive Value of [(99m)Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [(90)Y]-TARE: A Single-Center Experience
por: Doppler, Michael, et al.
Publicado: (2023)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
por: Kim, Jung Hee, et al.
Publicado: (2017)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
por: Féray, Cyrille, et al.
Publicado: (2023)

CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients
por: Bernatz, Simon, et al.
Publicado: (2023)

Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety
por: Li, Hui, et al.
Publicado: (2019)

Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies
por: Liang, Jing, et al.
Publicado: (2019)

Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
por: Wu, Jianbing, et al.
Publicado: (2017)

Transarterial Radioembolization (TARE) with (131) Iodine-Lipiodol for Unresectable Primary Hepatocellular Carcinoma: Experience from a Tertiary Care Center in India
por: Patel, Aakash, et al.
Publicado: (2021)

Comparison of a multitarget blood test to ultrasound and alpha‐fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta‐analysis
por: Singal, Amit G., et al.
Publicado: (2022)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
por: Chen, Li, et al.
Publicado: (2021)

PRM-MS Quantitative Analysis of Isomeric N-Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma
por: Gutierrez Reyes, Cristian D., et al.
Publicado: (2021)

Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort
por: Parikh, Neehar D., et al.
Publicado: (2022)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021)

Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Duan, Ruihua, et al.
Publicado: (2023)

Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma
por: Parikh, Neehar D., et al.
Publicado: (2022)

PET/CT with (18)F-choline or (18)F-FDG in Hepatocellular Carcinoma Submitted to (90)Y-TARE: A Real-World Study
por: Filippi, Luca, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma
por: Cai, Yeyu, et al.
Publicado: (2018)

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE
por: Huang, Wu-Kui, et al.
Publicado: (2017)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
por: Wang, Yujia, et al.
Publicado: (2022)

Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study
por: Xiang, Hua, et al.
Publicado: (2019)

Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm
por: Cho, Su Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8gddvnaqj1lgod1ikhkcl61tk5